🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued

Science Day revealed a much bigger story than COVID vaccines: AI-powered drug discovery, personalized cancer medicines, in vivo CAR-T, and one of biotechnology's most ambitious platforms.

Inside Moderna's expanding pipeline, $7.5 billion balance sheet, 16% short interest, Fidelity's 11.5% stake, and why we believe fair value approaches $100 despite substantial risks.

For years, investors have viewed Moderna through a single lens.

COVID.

That made sense.

Its vaccine changed the course of the pandemic, generated tens of billions of dollars in revenue, and proved that messenger RNA could become one of medicine's most important new technologies.

But here's the problem.

The market is still largely valuing Moderna as though COVID represents its future.

We think that's increasingly outdated.

Today's Moderna is becoming something far more ambitious:

A programmable medicine platform.

At its recent Science Day, management showcased advances that extended well beyond respiratory vaccines.

Personalized cancer vaccines.

Autoimmune therapies.

Rare disease programs.

AI-assisted drug discovery.

Even in vivo CAR-T, one of biotechnology's most exciting frontiers.

That's a very different company than the one Wall Street fell in love with—or fell out of love with—during the pandemic.

And that's exactly why we're becoming increasingly optimistic.

🚀 FUNanc1al Atomic Statements

🗣️ The Platform Principle™

"The market values Moderna as though it sells vaccines. We value Moderna as though it builds medicines."

🗣️ The Messenger Principle™

"Messenger RNA isn't a product. It's a manufacturing language."

Think about that for a moment.

Traditional biotechnology often develops one molecule...

...for one disease.

Messenger RNA can potentially become an entire operating system capable of generating medicines across dozens of therapeutic areas.

If successful, each breakthrough doesn't merely create another product.

It expands the platform itself.

🗣️ The Platform Compounding Principle™

"Every successful mRNA program doesn't simply create one medicine—it increases the probability of the next."

That's what makes platform companies different.

Each success strengthens future research.

Each manufacturing improvement benefits multiple programs.

Each regulatory approval teaches valuable lessons that can accelerate future development.

Platforms compound.

Individual drugs generally don't.

⏪ Looking Back: When the Market Didn't Believe

One year ago, the mood surrounding Moderna couldn't have been more different.

COVID revenues were fading.

Wall Street had largely moved on.

The stock looked broken.

Many investors had concluded that Moderna's best days were behind it.

We disagreed.

Back in June 2025, when Moderna traded around $25.90, we published:

"Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — 'Discount!'"

At the time, we wrote:

"Let's rewind to March 3, 2025. The stock was trading around $31. Fast forward three months, and it's down another 20%, sitting near $25.90.

But here's the spicy part...

CEO Stéphane Bancel shelled out more than $5 million of his own money—not stock options, not restricted stock units, but honest-to-goodness cold hard cash.

Director Paul Sagan followed with another $1 million of his own.

That's not symbolic confidence.

That's 'put your yacht-money where your mouth is' confidence." 🛥️

Our conclusion?

🛒 Our Take: A speculative—but possibly brilliant—Buy.

Since then, the stock has more than doubled, including a 12.6% jump on June 26, 2026, following Moderna's Science Day and renewed enthusiasm surrounding its expanding pipeline.

Of course, one successful call doesn't guarantee the next one.

Markets remain unpredictable.

Clinical trials remain uncertain.

Biotechnology remains volatile.

But we believe the original thesis has actually become stronger.

Back then, we primarily saw a deeply discounted mRNA leader.

Today, we see something bigger:

A company evolving into one of the world's most ambitious programmable medicine platforms.

That's why, despite the stock's impressive recovery, we continue to believe Moderna remains undervalued over the long term.

Our fair value estimate remains approximately $100 per share, recognizing that biotechnology investing is inherently speculative and subject to significant scientific, regulatory, commercial, and financial risks.

🚀 Trigger #1 — Science Day Changed the Conversation

Every company has moments that redefine its future.

For Moderna, Science Day may prove to be one of them.

Instead of focusing primarily on COVID boosters, management presented a vision of a diversified biotechnology platform spanning oncology, immunology, infectious disease, rare disorders, and regenerative medicine.

Among the highlights:

🧬 Personalized cancer vaccines.

🧬 Autoimmune therapies.

🧬 In vivo CAR-T research.

🧬 Next-generation respiratory vaccines.

🧬 AI-enhanced drug discovery.

The takeaway wasn't simply that Moderna has "more products."

It was that Moderna increasingly resembles a biotechnology platform capable of generating entirely new categories of medicines.

That's a profound distinction.

💡 Why AI Matters More Than Many Investors Realize

Artificial intelligence isn't replacing Moderna's scientists.

It's making them more productive.

Machine learning now assists researchers in:

🔬 Selecting better molecular candidates.

🧬 Optimizing mRNA sequences.

⚙️ Improving manufacturing efficiency.

📊 Predicting biological interactions.

⏳ Reducing development timelines.

Every month saved in drug development can translate into enormous value—for patients and shareholders alike.

If AI helps Moderna identify stronger candidates earlier, the impact won't be limited to one therapy.

It could improve the productivity of the entire platform.

That's precisely the type of compounding effect long-term investors should look for.

🧪 Trigger #2 — Moderna Is No Longer "The COVID Company"

Perhaps the biggest misconception surrounding Moderna is that it remains dependent on one product.

The pipeline tells a very different story.

Today, and as indicated above, Moderna is pursuing therapies across multiple therapeutic areas, including:

🫁 Respiratory diseases.

🎗️ Oncology.

🧬 Rare genetic disorders.

🦴 Autoimmune diseases.

🛡️ Latent viruses.

🧠 Emerging infectious diseases.

Each program carries risk.

Many won't succeed.

That's biotechnology.

But investors don't need every program to become a blockbuster.

If even a handful ultimately reach commercial success, today's valuation could look remarkably conservative in hindsight.

That's why we continue viewing Moderna through a platform lens rather than a product lens.

We're not investing in one vaccine.

We're investing in one of the world's most advanced programmable medicine platforms.

🏦 Trigger #3 — Smart Money Still Believes

One of the most encouraging aspects of Moderna's ownership profile is who continues to stand behind the company.

Institutional investors own roughly 79% of outstanding shares.

Among the largest holders is Fidelity Management & Research, which owns approximately 11.5% of Moderna.

That's noteworthy.

Large institutional investors don't simply evaluate last quarter's revenue.

They evaluate scientific platforms, competitive advantages, intellectual property, capital allocation, and long-term optionality.

Moderna continues attracting precisely the type of patient capital capable of looking years—not quarters—ahead.

Meanwhile...

Approximately 16% of the public float remains sold short.

That's substantial.

Why?

Some investors continue viewing Moderna primarily through the lens of declining COVID revenues and accumulating losses, resulting in substantial cash burn. The firm reported its Q1 2026 earnings on May 1, 2026, posting an EPS loss of $-3.40. Despite the net loss of $(1.3) billion—largely impacted by a $900 million non-recurring litigation settlement—quarterly revenue reached $389 million, representing a 264% year-over-year increase that strongly beat Wall Street estimates.

Others question whether enough pipeline programs will ultimately reach commercialization.

Those concerns are understandable.

Biotechnology investing has always required balancing extraordinary upside against meaningful scientific uncertainty.

But should Moderna continue producing encouraging clinical data, the combination of improving sentiment and elevated short interest could amplify future upside.

Short squeezes should never become an investment thesis.

They can, however, become an interesting accelerant.

For Moderna (NASDAQ: MRNA)'s Institutional Ownership breakdown, 🔍 see here.

💰 Trigger #4 — Valuation: Looking Beyond Today's Earnings

Traditional valuation metrics often struggle with platform companies.

Early Amazon looked expensive.

Early NVIDIA looked expensive.

Many revolutionary businesses appeared expensive precisely because investors focused on current earnings rather than future cash flows.

Biotechnology presents a similar challenge.

Today's Moderna isn't being built to maximize next quarter's profits.

It's investing aggressively to create a portfolio capable of generating recurring revenue across multiple therapeutic areas for decades.

That's a very different exercise.

The market continues assigning considerable weight to declining COVID vaccine sales.

We believe investors should increasingly focus on something else:

What could Moderna become once multiple pipeline programs mature simultaneously?

That's the real valuation question.

Not:

"What did Moderna earn last quarter?"

But:

"What could this platform earn ten years from now?"

Based on our assessment of Moderna's technology, pipeline breadth, financial resources, and long-term commercial potential, we continue to believe that fair value approaches $100 per share, acknowledging that biotechnology valuations remain inherently uncertain and highly sensitive to clinical outcomes.

That doesn't mean the stock will move there quickly (although it might, given recent momentum).

Markets rarely travel in straight lines.

Neither do biotech stocks.

 👉 Want the full picture? Dive into Moderna (NASDAQ: MRNA)'s financials here.

📈 Trigger #5 — Why We Remain Bullish

We liked Moderna before.

We arguably like it even more today.

Not because every clinical program will succeed.

They won't.

That's the nature of drug development.

We remain constructive because the platform itself continues expanding.

Every new indication.

Every manufacturing improvement.

Every AI-assisted discovery.

Every successful clinical trial.

Every regulatory approval.

Each one strengthens the broader ecosystem.

That's precisely how platforms compound.

The investment thesis isn't dependent upon a single blockbuster.

It's based on the growing probability that multiple independent opportunities eventually create a much larger business than today's valuation implies.

For long-term investors willing to accept volatility...

That's an attractive proposition.

😂 A Little Biotech Humor

🧬 The Messenger

Messenger RNA.

Finally...

A messenger everyone actually wants to hear from.

🧪 Moderna's Biggest Problem

For years investors kept saying:

"Moderna only has COVID."

Now they have a different challenge.

Keeping track of the pipeline.

🔬 Clinical Trials

Being a biotech investor is simple.

One day you're celebrating a breakthrough.

The next day you're learning scientific terms you can't pronounce.

Fortunately...

The scientists usually can.

📌 Signal Extract

"Messenger RNA isn't a product. It's a manufacturing language."

🎯 High-Conviction Takeaway

"The market values Moderna as though it sells vaccines. We value Moderna as though it builds medicines."

❓ Frequently Asked Questions (FAQ)

Isn't Moderna still dependent on COVID vaccines?

Far less than many investors believe.

COVID vaccines remain an important source of revenue, but Moderna is steadily expanding into oncology, respiratory diseases, rare diseases, autoimmune conditions, and other therapeutic areas.

The long-term investment case increasingly rests on the platform—not one product.

Why is the pipeline so important?

Because diversification reduces dependence on any single commercial success.

Biotechnology is inherently uncertain.

A broad pipeline creates multiple opportunities for future value creation while spreading scientific risk across numerous programs.

What are the biggest risks?

Several remain significant:

• Clinical trial failures.

• Regulatory setbacks.

• Continued cash burn.

• Commercial execution.

• Competitive pressure.

• Pricing and reimbursement challenges.

Biotechnology investing has never been risk-free.

Neither is Moderna.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

Why does FUNanc1al assign an 8.7?

Because we evaluate businesses over years—not headlines.

The scientific platform, financial flexibility, manufacturing expertise, intellectual property, and expanding pipeline collectively create a business we believe deserves a premium long-term valuation despite substantial execution risk.

⚡ Quick Take (TL;DR)

Bullish

✅ One of the world's leading mRNA platforms.

✅ Nearly 50 development programs.

✅ Personalized cancer vaccines.

✅ AI-powered research.

✅ Approximately $7.5 billion cash position.

✅ Strong institutional ownership.

✅ Platform economics becoming increasingly compelling.

Bearish

⚠ Clinical failures remain inevitable.

⚠ Revenue still normalizing after COVID.

⚠ Significant R&D spending.

⚠ Regulatory uncertainty.

⚠ High biotech volatility.

🍔 Food for Thought

Perhaps the biggest lesson isn't about Moderna.

It's about innovation itself.

The world often remembers breakthrough products.

Investors should pay attention to breakthrough platforms.

The internet became larger than websites.

Smartphones became larger than phones.

Artificial intelligence is becoming larger than chatbots.

Messenger RNA may prove larger than vaccines.

Sometimes the greatest opportunities emerge when a new technology evolves from solving one problem...

...into solving many.

Long-term investing often means recognizing that transition before everyone else does.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al, where investing meets curiosity, science, humor, and long-term thinking.

A lifelong entrepreneur, investor, technologist, and storyteller, he combines rigorous financial analysis with behavioral finance and a touch of comedy to help readers make better decisions while actually enjoying the process.

Beyond investing, Frédéric is the founder of Cl1Q, writes screenplays and novels, explores artificial intelligence, and believes that life's greatest returns often come from continuously learning, laughing, and pursuing new passions.

Because building wealth should never require abandoning wonder.

📊 FUNanc1al Disclosure

FunStock Index™: 8.7 / 10

The FunStock Index™ represents FUNanc1al's proprietary long-term assessment of business quality, competitive positioning, innovation, financial strength, execution, capital allocation, valuation, industry dynamics, and future growth potential.

An 8.7/10 reflects our belief that Moderna remains one of the world's most innovative biotechnology companies and one of the highest-quality long-term platform opportunities in healthcare.

We aren't betting on one vaccine.

We're investing in the possibility that messenger RNA becomes one of the defining medical technologies of the next generation.

And if that future unfolds, today's valuation may eventually look surprisingly modest.